Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4A 10

Next Previous
Drug Profile

4A 10

Alternative Names: 4A-10; 4A10 antibody therapy - Allterum Therapeutics

Latest Information Update: 02 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Allterum Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 7 receptor alpha subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 11 Nov 2025 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA (Parenteral) prior to November 2025
  • 11 Nov 2025 4A 10 receives Fast Track designation for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) (Parenteral) in USA
  • 11 Nov 2025 Allterum Therapeutics plans a phase I/IIa trial for Precursor-cell-lymphoblastic-leukaemia-lymphoma in the first quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top